A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Head and Neck Cancer
Latest Information Update: 28 Apr 2023
At a glance
- Drugs R-130 (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 28 Apr 2023 New trial record